Kataldi

Chlortalidone, the active ingredient in Kataldi, is a thiazide‑like diuretic presented as an oral tablet for oral use. It lowers elevated blood pressure and reduces fluid retention in patients with hypertension or edema. GNH USA supplies Kataldi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kataldi, a thiazide‑like diuretic, is employed in the management of conditions related to excess fluid and high blood pressure. Hypertension: reduces systemic vascular resistance and plasma volume, contributing to sustained blood pressure control. Edema: increases urinary excretion of sodium and water, alleviating fluid accumulation in peripheral tissues.

Common Side Effects: - Low blood sodium (hyponatremia) - Low blood potassium (hypokalemia) - Elevated uric acid levels (hyperuricemia) - Increased blood glucose levels - Dizziness or light‑headedness

Serious or Rare Side Effects: - Severe electrolyte imbalance requiring medical attention - Acute pancreatitis - Allergic reactions such as rash, itching, or swelling - Blood dyscrasias (e.g., agranulocytosis) - Hepatic dysfunction

Before initiating therapy, clinicians should consider several safety measures. Monitor electrolytes: regular blood tests to assess sodium, potassium, and uric acid levels. Assess renal function: evaluate creatinine clearance, especially in patients with existing kidney disease. Evaluate blood pressure: ensure adequate control without excessive hypotension. Use cautiously in diabetes: monitor glucose as chlortalidone may raise blood sugar. Avoid in severe hepatic impairment: liver dysfunction can exacerbate drug accumulation. Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Chlortalidone may interact with several medicines, requiring attention to avoid adverse outcomes. Major Interactions (Avoid): - Lithium: increased lithium levels and toxicity. - NSAIDs: reduced diuretic efficacy and possible renal impairment. - ACE inhibitors: heightened risk of hyperkalemia and renal dysfunction.

Moderate Interactions (Monitor Closely): - Beta‑blockers: additive blood‑pressure lowering effect. - Antidiabetic agents: possible increase in blood glucose. - Anticoagulants: enhanced anticoagulant effect, requiring INR monitoring.